Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, P. O. Box 14155/6117, 14166/43931 Tehran, Iran.
Liver Transplantation Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Clin Nutr. 2019 Jun;38(3):1153-1165. doi: 10.1016/j.clnu.2018.06.979. Epub 2018 Jul 2.
Several studies have shown effects of anthocyanin on blood pressure, blood glucose, and lipid profile in different conditions, but the results of these studies are controversial. We summarized evidence from randomized clinical trials (RCTs) that investigated the effects of anthocyanin supplementation on cardio-metabolic biomarkers in adults.
The literature searches of MEDLINE and EMBASE for published studies in English was performed up to August 2017. Results were summarized as mean differences (MD) with 95% confidence intervals (CI). Effect sizes of eligible studies were pooled using random-effects models (the DerSimonian-Laird estimator). Heterogeneity among studies was evaluated by the Cochrane Q test.
Of 5370 papers, 19 RCTs met inclusion criteria. There was no significant effect of anthocyanin supplementation on weight, waist circumference (WC), body mass index (BMI), systolic and diastolic blood pressure (SBP and DBP). Our results indicated that anthocyanin supplementation had no significant effects on HbA1c (MD: -0.32; 95% CI = -0.64, 0.00; p = 0.050) with no heterogeneity (I = 0.0%, p = 0.966, no significant heterogeneity), however anthocyanin supplementation had significant effect on HOMA-IR (MD: -0.21; 95% CI = -0.36, -0.07; p = 0.004) (I = 37.9%, p = 0.200, no significant heterogeneity) in adults. Intake of anthocyanin had no significant effects on FBS (MD: 0.25; 95% CI = -5.70, 6.21; p = 0.933) and serum insulin (MD: 0.09; 95% CI = -0.92, 1.11; p = 0.860) with high heterogeneity for these variables (p = 0.000, and I = 83.5%) and (p = 0.098, and I = 52.4%), respectively. Anthocyanin supplementation had significant effects on total cholesterol (TC) and low density lipoprotein (LDL) for more than 300 mg/day intervention for more than 12 weeks. The dose and duration of supplementation were the potential sources of heterogeneity among most of the trials.
The results demonstrate that supplementation with anthocyanin have beneficial effect on HOMA-IR in adults.
多项研究表明，花色苷对不同情况下的血压、血糖和血脂谱有影响，但这些研究的结果存在争议。我们总结了已发表的英文文献中随机临床试验（RCT）的证据，这些研究调查了花色苷补充剂对成年人心脏代谢生物标志物的影响。
对 MEDLINE 和 EMBASE 进行文献检索，以检索截至 2017 年 8 月发表的研究。结果以均数差值（MD）和 95%置信区间（CI）表示。使用随机效应模型（DerSimonian-Laird 估计值）汇总合格研究的效应大小。通过 Cochrane Q 检验评估研究间的异质性。
在 5370 篇论文中，有 19 项 RCT 符合纳入标准。花色苷补充剂对体重、腰围（WC）、体重指数（BMI）、收缩压和舒张压（SBP 和 DBP）没有显著影响。我们的结果表明，花色苷补充剂对 HbA1c 没有显著影响（MD：-0.32；95%CI：-0.64，0.00；p=0.050），异质性不显著（I=0.0%，p=0.966，无显著异质性），但花色苷补充剂对 HOMA-IR 有显著影响（MD：-0.21；95%CI：-0.36，-0.07；p=0.004）（I=37.9%，p=0.200，无显著异质性）。成年人摄入花色苷对空腹血糖（MD：0.25；95%CI：-5.70，6.21；p=0.933）和血清胰岛素（MD：0.09；95%CI：-0.92，1.11；p=0.860）没有显著影响，这些变量的异质性很高（p=0.000，I=83.5%）和（p=0.098，I=52.4%）。花色苷补充剂对总胆固醇（TC）和低密度脂蛋白（LDL）的影响超过 300mg/天，持续时间超过 12 周。补充剂的剂量和持续时间是大多数试验中出现异质性的潜在原因。
结果表明，花色苷补充剂对成年人的 HOMA-IR 有有益的影响。
